“What do you think?” – multiple people started conversations this way in Chicago this past weekend at the 2026 American Heart Association (AHA) Scientific Sessions. We knew exactly what they were asking about without requiring clarification.
The primary results from the phase III HORIZON Lp(a) trial was one of the most anticipated and memorable Late Breaker presentations at an AHA meeting. We knew the topline results (“did not achieve primary endpoints”) that were released two months before, but most of us expected to see something different than what was ultimately revealed – no difference in risk for outcomes between pelacarsen, the antisense oligonucleotide designed to lower lipoprotein(a) [Lp(a)], and placebo. In exploratory analyses, there were no differences in subgroups, including, no difference between those with high versus very high baseline Lp(a) levels, no difference between coronary disease and stroke patients, no difference between those in the pelacarsen group who remained on drug versus those who stopped early because of side effects…NO DIFFERENCE.
Pelacarsen lowered Lp(a) levels as expected, by ~78% (~170 nmol/L), and lowered LDL-cholesterol (LDL-C) levels by ~13% (~9 mg/dL), but there was still no difference in risk for cardiovascular outcomes.
If you are struggling to understand why, you are not alone.
We know
- There is a strong association between Lp(a) level and cardiovascular (CV) risk (coronary artery disease [CAD], myocardial infarction, stroke, peripheral artery disease, and aortic stenosis [AS]);
- There is a strong genetic association between LPA gene variants and risk for those same CV outcomes;
- There is no apparent threshold of Lp(a) level and risk – it is graded and proportional to the Lp(a) level;
- The risk with elevated Lp(a) is higher for CAD and AS compared to stroke;
- The biology of Lp(a) supports multiple potential, complementary mechanisms that can promote atherogenesis and plaque destabilization – atherogenic characteristics, antifibrinolytic effect with plasminogen inhibition, proinflammatory effect of oxidized phospholipids;
- Multiple Lp(a)-lowering drugs in development look extremely effective and safe for Lp(a)-lowering.
Why didn’t it work?
- Did pelacarsen cause harm that offset the benefits of the Lp(a) and LDL-C lowering? The most compelling aspect of this possibility is the lack of benefit over 4.7 years median follow-up despite ~9 mg/dL lowering of LDL-C levels.
- Was pelacarsen started too late? –
- was it started too late to prevent atherogenesis?
- does Lp(a) even have an impact on plaque destabilization/events?
- was it ineffective because all other risk factors were optimally managed overshadowing the Lp(a) effect?
- Maybe we have the biology wrong. It’s happened before. It was only about a decade ago, that we all thought raising HDL-cholesterol (HDL-C) would reduce CV risk. We didn’t have a full grasp on the complexity of HDL biology. Could some aspect of Lp(a) still need to be clarified to explain how/why reducing circulating Lp(a) levels does not reduce CV risk? There is a lot more to learn about Lp(a) for sure.
- Was the Lp(a) lowering with pelacarsen enough? The genetic studies had suggested a 65-100 mg/dL Lp(a) lowering to see a ~20% reduction in CV risk. The ~170 nmol/L Lp(a) lowering with pelacarsen may be at the lower end of this estimate.
The future
Assuming the ongoing Lp(a)-lowering clinical trials continue at the pace they are on, we will learn in the next 5 years whether more potent or Lp(a)-lowering through alternative mechanisms (e.g. with siRNAs) reduces CV risk in:
- Patients with established atherosclerotic cardiovascular disease (ASCVD)
- Adults without established disease but at high risk for ASCVD
- Adults with signs of early AS
To the patients
This is the hardest part. We have been so optimistic for a positive result, and our patients are scared.
We remind all our patients that in the United States, age-adjusted mortality from acute MI has fallen 89% from 1970-2022! Event rate is not mortality, and we can manage a large component of risk for CV events for those who seek and can access help. Back to the drawing board for Lp(a), but in the meantime we recommend:
- Optimal risk assessment including Lp(a) testing for all adults at least once.
- Follow AHA’s recommendation on Life’s Essential 8: eat better, be more active, manage weight, quit tobacco, get healthy sleep and manage stress, manage blood sugar, manage blood pressure and control cholesterol.
- Achieve LDL-C, non-HDL-C, and ApoB goals: lower for longer is better
- Anti-platelet therapy for those with ASCVD
- For some individuals, other interventions may offer additional lowering of CV risk, including GLP1RAs, icosapent ethyl, and colchicine.